Butterfly Network operates in industries such as electronics, healthcare, medical devices, personal health, and software. The company was founded in 2011 by Jonathan Rothberg, Nevada Sanchez, and Tyler Ralston in Guilford, Connecticut, United States.
The company has developed their Ultrasound-on-Chip technology that is meant to replace the Piezo crystal transducer systems of older ultrasonography equipment with a single silicon chip. They also offer their app which features nineteen presets and familiar touch interactions. Presets on the app can be set for examines such as cardiac, abdomen, bladder, aorta, gallbladder, lung, musculoskeletal, and more. There are three modes available for use including B-mode, M-mode, and color doppler. Gain and depth can be measured and recorded via the app, as well as measurements.
Data that is used through the Butterfly iQ app is AES 256-bit encrypted, and can be stored and encrypted in the Butterfly Cloud as well. Transit from the Butterfly iQ app to the Butterfly Cloud is protected by HTTPS, TLS 1.2 encryption. SOC II certification must be used in order to access your user data.
In conjunction with Atrium Health, Butterfly Network has provided a portable ultrasound device to assist in the screening and monitoring processes involved with COVID-19. Atrium Health has provided the point-of-care ultrasound (POCUS) device, and Butterfly Network is producing it. The device is called the Butterfly iQ, and it is the first portable, single-probe, whole-body ultrasound device. It connects to a smartphone or tablet via the app, which allows for exam room or home visit examinations.
Butterfly iQ devices allow doctors to screen and monitor COVID-19 patients by providing an immediate picture of the patient's lungs. The device can be used to provide various scans to collect data on where the disease has effect on patients. The devices are active at over thirty 'high-priority' locations, such as COVID-19 testing centers, emergency departments, and intensive care units. The use of the portable device allows for patients to avoid spreading infection through a hospital due to the need of an X-ray or CT scan.
Longview Acquisition Corp. (NYSE:LGVW.U, LGVW, LGVW WS) , a special purpose acquisition company sponsored by an affiliate of Glenview Capital Management, LLC, announced today that its stockholders voted to approve the proposed business combination with Butterfly Network, Inc. with nearly 100% of the shares of Longview voted at the Special Meeting in favor of the business combination proposal.
Jonathan M. Rothberg
Butterfly Network - Crunchbase Company Profile & Funding
Butterfly Network and Atrium Health Drive Innovation During COVID-19 Battle | Butterfly iQ
COVID-19 lung ultrasound imaging: fighting together
One probe, whole-body imaging | Butterfly iQ
Documentaries, videos and podcasts
Jonathan M. Rothberg
Guilford, Connecticut, United States
Ultrasonography medical devices
- CompanyA company, abbreviated as "Co." within a company name, is a legal entity made up of an association of people, be they natural, legal, or a mixture of both, for carrying on a commercial or industrial enterprise.
- Unicorn VCVenture capital
- HealthcareDiagnosis, treatment and prevention of disease, illness, and injury
- Medical deviceInstrument, apparatus, implant, in vitro reagent, or similar or related article
- UltrasoundVibrations with frequencies above the human hearing range
- Point of Care UltrasoundPoint-of-care ultrasound (POCUS) is the application of ultrasound at the point of care to make immediate patient-care decisions, often to evaluate an emergency medical condition. POCUS is rapidly replacing the stethoscope at the bedside, providing immediate diagnoses often with greater sensitivity and specificity than chest x-rays and CT.
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.